Inflammatory intestinal diseases
Cure8 research brief
Why This Matters
Early symptomatic improvement on filgotinib may predict longer-term gains in disease-specific quality-of-life for people with ulcerative colitis, which could help patients and clinicians set expectations during treatment.
Who Should Pay Attention
Adults with ulcerative colitis; clinicians managing UC; researchers interested in IBD treatment outcomes and quality-of-life measures.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This article reports a post hoc analysis of SELECTION and its long-term extension (SELECTIONLTE) looking at quality-of-life (IBDQ) and individual bowel/systemic symptom scores in patients with ulcerative colitis treated with filgotinib 200 mg.
The analysis followed 148 patients who completed induction and maintenance and continued FIL200 through LTE Week 96, comparing IBDQ total and subscore changes at Week 10, Week 58, and LTE Week 96 and assessing associations between early symptomatic remission and long-term IBDQ remission.
Key findings described in the abstract: FIL200-treated patients showed larger improvements in IBDQ total and bowel/systemic subscores if they achieved symptomatic (pMCS) remission at Week 10, and Week 10 symptomatic remission was modestly associated with higher odds of IBDQ remission at LTE Week 96.
The authors conclude that early symptomatic improvement provides information about sustained quality-of-life benefit.
Keep In Mind
Post hoc analyses are exploratory. The abstract summarizes results from trial participants who continued filgotinib into a long-term extension; it does not replace the primary randomized trial outcomes or provide full safety details.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationInflammatory intestinal diseases
AuthorsHirai F, Rudolph C, Kaise T +1 more
Study typeJournal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedJan 1, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Multicentre retrospective real-world evidence study evaluating the effectiveness and safety of mirikizumab in patients with moderately to severely active ulcerative colitis.
Real-world data show how mirikizumab performs outside clinical trials, especially in patients previously exposed to multiple advanced therapies. That can help patients and clinicians weigh expectations for effectiveness...
Subcutaneous Guselkumab Proves Efficacious for IBD in Two Studies: ASTRO and GRAVITI
These are phase 3 results showing subcutaneous guselkumab helped more people reach clinical and endoscopic goals than placebo in moderate-to-severe UC and Crohn’s disease; a fully subcutaneous option could offer more...
Upadacitinib as a rescue therapy for steroid- and infliximab-refractory acute severe ulcerative colitis: short- and long-term effectiveness and safety in a multicenter cohort study
For patients and clinicians facing steroid- and infliximab-refractory acute severe ulcerative colitis, upadacitinib may be a third-line medical option that can produce rapid symptom and CRP improvement and allow some...